Publications

Liu K, Samuel M, Tillett J, Hennan JK, Mekonnen B, Soloveva V, Harrison RK, Paslay, JW, Larocque J. (2010). High-Throughput Screening for Kv1.3 Channel Blockers Using an Improved FLIPR-Based Membrane-Potential Assay Journal of Biomolecular Screening 2010. 15:185-195
download here...(pdf file 1.86 MB)

Franke AA,  Halm BM, Kakazu K, Li X, Custer LJ. (2009). Phytoestrogenic isoflavonoids in epidemiologic and clinical research. Drug Testing and Analysis 2009. 1:14-21
download here...(pdf file 376 KB)

Karczewski J, Wang J, Kane SA, Kiss L, Koblan KS, Culberson C, Spencer RH. (2009). Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel. Biochemical Pharmacology 2009 (77) 1561-1654
download here...(pdf file 1 MB)

Karczewski J, Kiss L, Kane SA, Koblan KS, Lynch RS, Spencer RS. (2009).High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5. Biochemical Pharmacology 77 177-185.
download here...(pdf file 637 KB)

Trivedi S, Dekermendjian K, Julien R, Huang J, Lund PE, Krupp J, Kronqvist R, Larsson O, Bostwick R. (2008). Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators. Assay Drug Dev Technol. 6 (2): 167-79.
download here...(pdf file 311KB)

Xiong Q, Sun H & Li M (2007). Zinc pyrithione-mediated activation of voltage-gatedKCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol 3 (5): 287-96.
download here...(pdf file 3.4MB)

Gill S, Gill R, Wicks D, & Liang D (2007). A Cell-based Rb⁺- Flux Assay of the Kv1.3 Potassium Channel. Assay Drug Dev Technol 5(3): 373-380.
download here...(pdf file 193KB)

Gill S, Gill R, Xie Y, Wicks D, & Liang D (2006). Development and Validation of HTS flux assay for endogenously expressed chloride channels in a CHO-k1 cell line. Assay Drug Dev Technol 4(1): 65-71.
download here...(pdf file 153KB)

Sun H, Liu X, Xiong Q, Shikano S  & Li M (2006). Chronic inhibition of cardiac Kir2.1 and hERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking. Journal of Biological Chemistry.
download here...(pdf file 875KB)

Murphy SM, Palmer M, Poole M, Padegimas L, Hunady K, Danzig J, Gill S, Gill R, Ting A, Sherf B, Brunden K & Stricker-Krongrad A (2006).Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.J Pharmacol Toxicol Methods. 54(1):42-55.
download here...(pdf file 227KB)

Gill S, Gill R, Poluektov D, Wicks D, & Liang D (2005).Development and evaluation of an Automated Cell-Based Flux Assay for HTS of hERG. American Biotechnology Laboratory, 23(13): 12-15.

Langenhan JM, Peters NR, Guzei IA, Hoffman FM & Thorson JS (2005). Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization. Proc Natl Acad Sci USA 102(35):12305-10.
download here...(pdf file 587KB)

Sorota S, Zhang XS, Margulis M, Tucker K & Priestley T (2005).  Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.  Assay Drug Dev Technol 3(1):47-57.
download here...(pdf file 129KB)

Gill S, Gill R, Wicks D, Despotovski S & Liang D (2004). Development of an HTS assay for Na⁺, K⁺-ATPase using nonradioactive rubidium ion uptake. Assay Drug Dev Technol 2(5):535-42.
download here...(pdf file 132KB)

Rezazadeh S, Hesketh JC & Fedida D (2004). Rb⁺ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ flux assay. J Biomol Screen. 9(7):588-97.
download here...(pdf file 700KB)

Stankovich L, Wicks D, Despotovski S & Liang D (2004). Atomic absorption spectroscopy in ion channel screening. Assay Drug Dev Technol 2(5):569-74.
download here...(pdf file 69KB)

Sun H, Shikano S, Xiong Q & Li M (2004). Function recovery after chemobleaching (FRAC): evidence for activity silent membrane receptors on cell surface. Proc Natl Acad Sci USA 101(48):16964-9.
download here...(pdf file 145KB)

Wang K, McIlvain, Tseng E, Kowal D, Jow F, Shen R, Zhang H, Shan QJ, He L, Chen D, Lu Q & Dunlop J (2004). Validation of an atomic absorption rubidium ion efflux assay for KCNQ/M-channels using the Ion Channel Reader 8000. Assay Drug Dev Technol 2(5): 525-34
download here...(pdf file 146KB)

Zheng W, Spencer RH & Kiss L (2004). High throughput assay technologies for ion channel drug discovery. Assay Drug Dev Technol 2(5) 543-52.
download here...(pdf file 1.1MB)

Gill S, Gill R, Lee SS, Hesketh JC, Fedida D, Rezazadeh S, Stankovich L & Liang D (2003). Flux assays in high throughput screening of ion channels in drug discovery. Assay and Drug Dev Technol 1(5):709-17.
download here...(pdf file 180KB)

Gill S, Gill R, Lee SS & Liang D (2003). A high throughput screening technology: Overcoming bottlenecks in ion-channel drug targets. Lab Focus, March 1, 2003.
Scott CW, Wilkins DE, Trivedi S & Crankshaw DJ (2003). A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry. Anal Biochem 319(2):251-7.
download here...(pdf file 161KB)

Parihar AS, Groebe DR, Scott VE, Feng J, Zhang XF, Warrior U, Gopalakrishnan M & Shieh CC (2003). Functional analysis of large conductance Ca²⁽⁺⁾-activated K⁽⁺⁾ channels: ion flux assay studies by atomic absorption spectrometry. Assay Drug Development Technology 1(5):647-54.
Zheng W & Kiss L (2003). Screening technologies for ion channel targets in drug discovery. American Pharmaceutical Review 6(4): 85-92
download here...(pdf file 525KB)

Technology Comparison

Tang W, Kang J, Wu X, Rampe D, Wang L, Shen H, Li Z, Dunnington D & Garyantes T (2001).
Development and evaluation of high throughput functional assay methods for hERG potassium channel. J Biomol Screen 6(5):325-31.
download here...(pdf file 177KB)

Xu J, Wang X, Ensign B, Li M, Wu L, Guia A & Xu J (2001). Ion-channel assay technologies: quo vadis? Drug Discov Today 6(24):1278-87.
download here...(pdf file 84KB)
Terstappen GC (2005).Ion Channel Screening Technologies Today. Drug Discov Today:
Technologies 2(2):133-40.

Flux Assays

Terstappen GC (2004). Non radioactive rubidium ion efflux assay and its applications in drug discovery and development. Assay Drug Dev Technol 2(5):553-9.
Terstappen GC (1999). Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay. Anal Biochem 272(2):149-55.

Cardiac Toxicity

S7B : The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) By Human Pharmaceuticals, step 5. May 2005.
download here...(pdf file 187KB)